Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | LAP3 | P28838 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771287 | 1.00 | EPHX1 (0.53) | EPHX1ANPEPMMP2SLC1A3SLC1A2 | |
| SCHEMBL16449742 | 0.79 | TAAR1 (0.46) | EPHX1 | |
| SCHEMBL3897052 | 0.79 | EPHX1 (0.41) | EPHX1SLC1A3SLC1A2SLC1A1ALPI | |
| SCHEMBL3903096 | 0.79 | CYP1A2 (0.49) | EPHX1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14625582 | 0.77 | TRPA1 (0.41) | EPHX1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3897048 | 0.77 | EPHX1 (0.39) | EPHX1SLC1A3SLC1A2SLC1A1ALPI | |
| SCHEMBL3508823 | 0.76 | HPGD (0.57) | EPHX1ANPEPMMP2SLC1A3SLC1A2 | |
| SCHEMBL9393441 | 0.75 | EPHX1 (0.70) | EPHX1ANPEPMMP2ALPIPKM | |
| SCHEMBL4886438 | 0.75 | ALPI (0.53) | EPHX1ANPEPMMP2SLC1A3SLC1A2 | |
| SCHEMBL860163 | 0.74 | EPHX1 (0.47) | EPHX1ANPEPMMP2SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451782-B1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9198899-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-8822522-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140107120-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637676-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-09-19 | — | — | US | disclosed |
| US-8350027-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2162442-B1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-2451782-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | EPHX1 1562/4885ANPEP 72/4885MMP2 1438/4885 |
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | EPHX1 1562/4885ANPEP 72/4885MMP2 1438/4885 |
| US-20140107120-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | EPHX1 1901/4885ANPEP 94/4885MMP2 1031/4885 |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | AGTR1, REN, AGTR2 | EPHX1 1901/4885ANPEP 94/4885MMP2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.